←
Christopher Yusuf Akhunbay-Fudge39 posts
Christopher Yusuf Akhunbay-Fudge avatar

Christopher Yusuf Akhunbay-Fudge

@CA_Fudge

Neurosurgery Registrar and PhD researcher investigating #Glioblastoma biology. Scuba diver, Mushroom forager, Bonsai enthusiast. Views are my own.

◷ Joined March 2020▧ 7 Photos and videos
Asim Sheikh avatar
⟳ Christopher Yusuf Akhunbay-Fudge retweeted
Asim Sheikh@ASheikhNeuro·Mar 12

Well done ⁦@CA_Fudge⁩ and Skull Base team for representing ⁦@LeedsHospitals⁩ ⁦@LTHTNEURO⁩ at #NASBS2026 in San Diego. 3 oral presentations, 2 posters and catch up with friends from around the globe. It was fantastic. linkedin.com/posts/asim-shei…

Christopher Yusuf Akhunbay-Fudge avatar
Christopher Yusuf Akhunbay-Fudge@CA_Fudge·13 Feb 2025

Fantastic exhibition showcasing the great work supported by @LDShospcharity. It has been a true honour and privilege to be a recipient of their generous funding. They make a real difference to patients.

We are so excited to launch ‘Our Research Story’ exhibition showcasing the people behind life-changing research taking place right here in Leeds!💜 More info: leedshospitalscharity.org.uk… @LeedsHospitals @UniversityLeeds @LeedsArtUni

Post attachment
Sky News avatar
⟳ Christopher Yusuf Akhunbay-Fudge retweeted
Sky News@SkyNews·22 Jan 2025

'We hope this inspires surgeons worldwide to keep pushing the surgical envelope.' Drs. James Robin and Jiten Parmar hail their "pioneering surgery" after removing a tumor through a woman's eye socket. trib.al/qeQpuBB 📺 Sky 501, Freeview and YouTube

3:00
Leeds Teaching Hospitals avatar
⟳ Christopher Yusuf Akhunbay-Fudge retweeted
Leeds Teaching Hospitals@LeedsHospitals·20 Jan 2025

🚨 Groundbreaking in Leeds! Surgeons at Leeds Teaching Hospitals made history, removing a skull base tumour through the eye socket using a minimally invasive technique. Ruvimbo Kaviya, 40, is the UK’s first patient to benefit from this innovative surgery by Mr. Asim Sheikh & Mr. Jiten Parmar. Full story👉 shorturl.at/1G7m4 #MedicalInnovation #LeedsTeachingHospitals #HealthcareAdvancements

Asim Sheikh avatar
⟳ Christopher Yusuf Akhunbay-Fudge retweeted
Asim Sheikh@ASheikhNeuro·18 Apr 2024

New approaches and technologies are only good if they benefit patients. Endoscopic Transorbital excision of cavernous sinus meningioma. Quick recovery, excellent access to tumour, complete excision with good operative views. Normal vision and eye movements post op. Images shared with permission and consent from patient. @SkullBaseLeeds @LTHTNEURO @AlbertoEqDS

Post attachmentPost attachmentPost attachmentPost attachment
Dr. Renee Read avatar
⟳ Christopher Yusuf Akhunbay-Fudge retweeted
Dr. Renee Read@RRead_Lab·20 Nov 2023

If you're interested in exploring postdoctoral opportunities in @NeuroOnc, you're invited to apply to a special postdoctoral recruiting event at Winship Cancer Institute of Emory University this March. Join our wonderful brian tumor research community! 🤩 winshipcancer.emory.edu/educ…

Christopher Yusuf Akhunbay-Fudge avatar
Christopher Yusuf Akhunbay-Fudge@CA_Fudge·5 Nov 2023

Advances in brain cancer research are happening due to organisations such as @LDShospcharity who have been instrumental in supporting my work. Huge thanks to them, my other funders (@RCSnews) and my research team @SCBT_Research @LeedsNeuro @CritchleyGroup. Paper to follow soon!

During Brain Tumour Awareness Week, we want to acknowledge your donations that helped fund brain cancer research at Leeds Teaching Hospitals NHS Trust. In 2021, we granted £200,000 to Christopher Fudge's research on glioma cells and tumour recurrence after surgery.

Post attachmentPost attachmentPost attachment
Stephen Price💙 avatar
⟳ Christopher Yusuf Akhunbay-Fudge retweeted
Stephen Price💙@Sjp58Price·4 Jun 2023

Such an important study. Congratulations to all the authors for this practice changing study.

NEJM@NEJM4 Jun 2023

Late breaking at #ASCO23: Mutations in isocitrate dehydrogenase 1 or 2 are common in low-grade glioma. The IDH inhibitor vorasidenib improved progression-free survival as compared with placebo. Full results of the INDIGO trial: nej.md/3N8N5dU